Calidi Biotherapeutics CLDI
NYSE CLDI
$1.06 -0.01 (-0.93%)
As of: Oct 1, 2026 · 12:58 PM EDT

Calidi Biotherapeutics (CLDI) Receivables (2022 - 2023)

Updated

Calidi Biotherapeutics (CLDI) recorded Receivables of $870.00 in Q2 2023.

Analysis

Calidi Biotherapeutics (CLDI) Receivables (2022 - 2023) Analysis & Trends

At the end of FY2022, Calidi Biotherapeutics reported Receivables of $1,740.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 19.05 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 13.82 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 12.56 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 9.64 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 15.68 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 10.23 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 5.06 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 12.49 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 2.13 Bn
10 Calidi Biotherapeutics 1.50 Mn -23.88 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 870.00
Dec 31, 2022 1,740.00
API Access

Calidi Biotherapeutics Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=CLDI&period=max&api_key=YOUR_API_KEY